rosiglitazone has been researched along with Liver Steatosis in 80 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (57.50) | 29.6817 |
| 2010's | 32 (40.00) | 24.3611 |
| 2020's | 2 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, L; Chen, T; Chen, Z; Ding, Y; Li, S; Lin, L; Ma, L; Peng, A; Qiu, N; Wang, G; Wei, Y; Xu, Q; Yang, J; Ye, X; Zheng, H | 1 |
| Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C | 1 |
| Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I | 1 |
| Chen, MT; Gao, DD; Huang, JS; Li, YX; Wang, HY | 1 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
| Gaekens, M; Gallacher, DJ; Hemmeryckx, B; Lijnen, HR; Lu, HR | 1 |
| Aragonès, G; Beltrán-Debón, R; Camps, J; García-Heredia, A; Geeraert, B; Holvoet, P; Joven, J; Pedro-Botet, J; Rodríguez-Gallego, E; Rull, A | 1 |
| Gu, YE; Liu, XC; Yao, Z | 1 |
| Chang, E; Choi, JM; Park, CY; Park, SW; Yang, SJ | 1 |
| Pugalendi, KV; Radhiga, T; Sundaresan, A | 1 |
| Albu, JB; Engelson, ES; Glesby, MJ; He, Q; Kotler, DP | 1 |
| Kavimani, S; Kesavanarayanan, KS; Prathiba, D; Priya, RJ; Selvakkumar, C | 1 |
| Gu, H; Hinds, TD; Khuder, SS; Lecka-Czernik, B; Najjar, SM; Qiu, B; Russo, L; Sanchez, ER; Stechschulte, LA; Warrier, M; Xu, Y; Yong, W; Zhang, M | 1 |
| Fu, N; Nan, YM; Yu, J | 1 |
| Bergman, J; Borra, R; Hällsten, K; Iozzo, P; Komu, M; Lautamäki, R; Nuutila, P; Parkkola, R; Sijens, PE | 1 |
| Fu, N; Liang, BL; Nan, YM; Wang, RQ; Wu, WJ; Yu, J; Zhao, JM; Zhao, SX | 1 |
| Dogru, T; Ercin, CN; Erdem, G; Sonmez, A; Tapan, S; Tasci, I | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Hong, TP; Liu, GQ; Liu, Z; Wang, HN; Wang, YR; Wei, XL; Wu, PX | 1 |
| Jain, S; Marotta, F; Prasad, GB; Sinha, PR; Yadav, H; Yadav, M | 1 |
| Arroyo, V; Clària, J; Dong, B; Ferré, N; González-Périz, A; Gronert, K; Horrillo, R; López-Parra, M; Martínez-Clemente, M; Morán-Salvador, E; Titos, E | 1 |
| Berger, JP; Berthiaume, M; Deshaies, Y; Festuccia, WT; Laplante, M; Thieringer, R | 1 |
| Kamal, MA; Qu, X; Seale, JP; Tan, Y | 1 |
| Akarca, U; Akyildiz, M; Batur, Y; Cetinkalp, S; Omer, Z; Yilmaz, C; Yilmaz, F | 1 |
| Yki-Järvinen, H | 1 |
| Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
| Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Halbron, M; Hartmann-Heurtier, A; Lenaour, G; Poynard, T; Ratziu, V | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Pappo, O; Peleg, E; Safadi, R; Schmilovitz-Weiss, H | 1 |
| Cheng, AS; Chu, ES; Lam, CN; Lee, CW; Sung, JJ; Wong, VW; Wu, CW; Yu, J | 1 |
| Qi, Z; Wang, H; Xie, M; Xue, J; Zhang, Y | 1 |
| Chan, L; Che, CM; Lam, KS; Lee, IK; Tam, PK; Wang, Y; Wu, D; Xu, A; Zhou, M | 1 |
| Baxter, JD; Collins, AR; Finegold, MJ; Gupte, AA; Hsueh, WA; Liu, JZ; Lyon, CJ; Minze, LJ; Moore, DD; Pratico, D; Ren, Y; Webb, P; Wiles, JR; Wong, ST | 1 |
| Chen, Q; Liu, B; Liu, S; Wu, HJ; Wu, JP; Zhang, ZQ; Zhu, L | 1 |
| Han, F; Kong, LB; Nan, YM; Wang, RQ; Wu, WJ; Yu, J; Zhao, SX | 1 |
| El-Agamy, DS; Said, SA | 1 |
| Chae, SW; Choi, JM; Kim, SW; Kim, WJ; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ; Yang, SJ | 1 |
| Białkowska, J; Borkowska, A; Czupryniak, L; Ignaczak, A; Jabłkowski, M; Kwiecińska, E; Loba, J; Omulecka, A; Pawłowski, M; Saryusz-Wolska, M; Szymańska-Garbacz, E | 1 |
| Harrison, SA; Jones, FJ; Shaw, JC; Torres, DM; Ward, JA; Williams, CD | 1 |
| Minhu, C; Yao, J; Zhi, M | 1 |
| Chen, Y; Jiang, BR; Lu, YL; Qiao, J; Wang, NJ; Yang, LZ; Ye, TT; Yu, J; Zhao, LJ | 1 |
| Chalasani, N; Corey, KE | 1 |
| Kamal, MA; Qu, X; Seale, JP; Sun, LQ; Tan, Y; Wang, X | 1 |
| Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N | 1 |
| Aguila, MB; Fraulob, JC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Baumann, U; Bhathal, PS; Brown, RM; Brunt, EM; Clouston, AD; Couper, RT; Dixon, JB; Ee, LC; Jonsson, JR; Manton, ND; Moschen, AR; Neuschwander-Tetri, BA; O'Brien, PE; Powell, EE; Richardson, MM; Skoien, R; Tilg, H; Weltman, M | 1 |
| Cooney, GJ; Ellis, B; Iglesias, MA; Jensen, PB; Kraegen, EW; Larsen, PJ; Sørensen, RV; Wassermann, K; Watson, DG; Wood, L; Ye, JM | 1 |
| Brewer, B; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Lambert, G; Matsusue, K; Reitman, ML; Ward, JM; Yim, SH | 1 |
| Bacon, BR; Brunt, EM; Hampton, K; Neuschwander-Tetri, BA; Sponseller, CA; Wehmeier, KR | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Birmingham, J; Buckingham, RE; Changani, KK; Hockings, PD; O'Brien, P; Osborne, J; Reid, DG; Saeed, N; Toseland, CN | 1 |
| Albanese, C; Brownlee, M; Donehower, LA; Fu, M; Harris, EL; Hulit, J; Johns, DC; Jones, JG; Li, Z; Neumeister, P; Novikoff, PM; Pattabiraman, N; Pestell, RG; Rohan, T; Sakamaki, T; Scherer, PE; Wang, C; Whitney, KD; Wu, K; Zhou, JN | 1 |
| Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR | 2 |
| Bacon, BR | 1 |
| Dufour, JF; Oneta, CM | 1 |
| Leiter, EH; Pan, HJ; Reifsnyder, P; Vance, DE; Xiao, Q | 1 |
| Bonyhay, L; Ratziu, V; Tahiri, M | 1 |
| Moreno Sánchez, D | 1 |
| Bujko, J; Dzieniszewski, J; Nowicka, G; Tacikowski, T; Walewska-Zielecka, B | 1 |
| Bakiner, O; Ertugrul, D; Guvener, ND; Sahin, M | 1 |
| Leiter, EH; Mistry, J; Pan, HJ; Reifsnyder, PC; Xiao, Q; Zhang, W | 1 |
| Chen, YE; Leiter, EH; Lin, Y; Pan, HJ; Vance, DE | 1 |
| Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ | 1 |
| Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S | 1 |
| Chung, CH; Leung, CH; Liu, SC; Wang, CH | 1 |
| Belury, MA; Liu, LF; Purushotham, A; Wendel, AA | 1 |
| Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S | 1 |
| Avsar, E; Celikel, C; Emekli, E; Eren, F; Haklar, G; Imeryuz, N; Tahan, V; Tozun, N; Uzun, H; Yavuz, D; Yuksel, M | 1 |
| Cui, JF; Jia, B; Wang, YD; Zhao, CY; Zhou, JY | 1 |
| Díaz-Sanjuán, T; García-Ruiz, I; Martínez, MA; Muñoz-Yagüe, T; Rodríguez-Juan, C; Solís-Herruzo, JA | 1 |
| Brunt, EM; Caldwell, SH; Davis, CA; Neuschwander-Tetri, BA; Park, SH; Patrie, JT; Redick, JA | 1 |
| Chen, DF; Wang, XM | 1 |
| Chalasani, N; Khashab, M | 1 |
| Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S | 1 |
| Avsar, E; Celikel, C; Imeryuz, N; Tahan, V; Tozun, N | 1 |
| Baik, SH; Bak, YT; Byun, KS; Choi, KM; Jo, NY; Kim, A; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE | 1 |
| Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F | 1 |
| Bektas, M; Coban, S; Corapcioglu, D; Doganay, B; Emral, R; Erden, E; Idilman, R; Mizrak, D; Ozden, A; Sayki, M; Soykan, I; Uysal, AR | 1 |
| Bernhardt, C; Bruckert, E; Charlotte, F; Giral, P; Grimaldi, A; Hartemann-Heurtier, A; Jacqueminet, S; Lacorte, JM; Podevin, P; Poynard, T; Ratziu, V; Serfaty, L | 1 |
| Atzpodien, E; Bedoucha, M; Boelsterli, UA | 1 |
7 review(s) available for rosiglitazone and Liver Steatosis
| Article | Year |
|---|---|
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Thiazolidinediones and the liver in humans.
Topics: Diabetes Mellitus, Type 2; Fats; Fatty Liver; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Review Literature as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2011 |
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss | 2004 |
[Nonalcoholic steatohepatitis].
Topics: Chronic Disease; Fatty Liver; Humans; Inflammation; Liver; Necrosis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Vasodilator Agents; Vitamin E Deficiency | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
12 trial(s) available for rosiglitazone and Liver Steatosis
| Article | Year |
|---|---|
The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.
Topics: Body Composition; Double-Blind Method; Fatty Liver; Female; Growth Hormone; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor I; Intra-Abdominal Fat; Liver; Male; Middle Aged; Rosiglitazone; Thiazolidinediones | 2016 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; gamma-Glutamyltransferase; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome | 2010 |
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Topics: Double-Blind Method; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease.
Topics: Adult; Case-Control Studies; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Losartan; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Body Weight; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Male; Middle Aged; Patient Dropouts; Pilot Projects; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2003 |
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Topics: Adult; Aged; Alanine Transaminase; Biopsy; Fatty Liver; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Treatment of nonalcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Female; Humans; Liver Function Tests; Male; Prognosis; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome | 2004 |
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
Topics: Biopsy; Blood Glucose; Fatty Liver; Female; Fibrosis; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Function Tests; Male; Middle Aged; Obesity; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Transcription Factors | 2004 |
Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Fatty Liver; Female; Fibrosis; gamma-Glutamyltransferase; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Necrosis; Placebos; Rosiglitazone; Thiazolidinediones | 2008 |
61 other study(ies) available for rosiglitazone and Liver Steatosis
| Article | Year |
|---|---|
Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; Barbiturates; Cell Differentiation; Disease Models, Animal; Fatty Liver; Leptin; Male; Mice; Molecular Structure; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Thiobarbiturates | 2011 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides | 2012 |
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity.
Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone | 2020 |
Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acid-Binding Proteins; Fatty Liver; Hepatocytes; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; Obesity; Primary Cell Culture; Rosiglitazone; Triglycerides | 2021 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |
Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Cholesterol, Dietary; Diabetes Mellitus; Diet, High-Fat; Fatty Liver; Gene Expression; Genotype; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Tyrosine | 2013 |
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Metabolome; Mice; Mice, Transgenic; Obesity; Peroxisome Proliferator-Activated Receptors; Protein Interaction Mapping; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcriptome | 2014 |
Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats.
Topics: Animals; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Dietary Fats; Drugs, Chinese Herbal; Fatty Liver; Liver; Male; Malondialdehyde; Non-alcoholic Fatty Liver Disease; Phytotherapy; Random Allocation; Rats; Rats, Wistar; Rosiglitazone; Schisandra; Superoxide Dismutase; Thiazolidinediones | 2014 |
Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
Topics: Animals; Cell Line; Fatty Liver; Gene Knockdown Techniques; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Rats; Rosiglitazone; Signal Transduction; Sirtuin 1; Sirtuins; Thiazolidinediones | 2014 |
Effect of ursolic acid and Rosiglitazone combination on hepatic lipid accumulation in high fat diet-fed C57BL/6J mice.
Topics: Animals; Diet, High-Fat; Drug Therapy, Combination; Fatty Acids; Fatty Liver; Male; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triterpenes; Ursolic Acid | 2014 |
Herbal formulation, DIA-2 and Rosiglitazone ameliorates hyperglycemia and hepatic steatosis in type 2 diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Liver; Hyperglycemia; Hypoglycemic Agents; Liver Diseases; Plant Extracts; Random Allocation; Rats; Rosiglitazone; Thiazolidinediones | 2015 |
FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.
Topics: Adiposity; Animals; Energy Metabolism; Fatty Liver; Glucose Intolerance; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Mice, Knockout; Obesity; PPAR gamma; Rosiglitazone; Tacrolimus Binding Proteins; Thiazolidinediones; Weight Gain | 2016 |
[Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis].
Topics: Animals; Fatty Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Rosiglitazone; Serum; Thiazolidinediones | 2008 |
Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones | 2008 |
Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blotting, Western; Connective Tissue Growth Factor; Fatty Liver; Hepatic Stellate Cells; Hypoglycemic Agents; Immunoenzyme Techniques; Liver Cirrhosis; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1 | 2009 |
Rosiglitazone for nonalcoholic steatohepatitis.
Topics: Blood Glucose; Fatty Liver; Glucose Tolerance Test; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.
Topics: Animals; Caspase 1; Disease Models, Animal; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Interleukin-18; Liver; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2008 |
Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats.
Topics: Animals; Epigenesis, Genetic; Fatty Liver; Fructose; Gluconeogenesis; Glucose Metabolism Disorders; Glycogen; Hypoglycemic Agents; Male; Rats; Rosiglitazone; Sweetening Agents; Thiazolidinediones | 2009 |
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.
Topics: Adiponectin; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Chemokine CCL2; Diet; Dietary Fats; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Liver; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Obese; Muscle, Skeletal; Obesity; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones | 2009 |
Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiponectin; Animals; Disease Models, Animal; Fatty Liver; Male; Obesity; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Rosiglitazone; Thiazolidinediones; Triazoles; Triglycerides | 2009 |
Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease.
Topics: Adipose Tissue; Alanine Transaminase; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Blood Glucose; Butyrylcholinesterase; Diabetes Mellitus, Type 2; Dietary Fats; Drugs, Chinese Herbal; Fatty Liver; Inflammation; Interleukin-6; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2009 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
Topics: Adiponectin; alpha-Tocopherol; Animal Feed; Animals; Aryldialkylphosphatase; Blood Pressure; Fatty Liver; Fructose; Glutathione Reductase; Hypoglycemic Agents; Lipid Metabolism; Lipids; Liver; Liver Cirrhosis; Male; Malondialdehyde; Metabolic Syndrome; Phospholipids; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
PPARgamma is essential for protection against nonalcoholic steatohepatitis.
Topics: Adenoviridae; Animals; Choline Deficiency; Fatty Liver; Gene Transfer Techniques; Genetic Therapy; Methionine; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Topics: Adiponectin; Animals; Blood Glucose; Cnidium; Coumarins; Dietary Fats; Dietary Sucrose; Fatty Liver; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Insulin; Insulin Resistance; Lipids; Liver; Male; Peroxisome Proliferator-Activated Receptors; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2011 |
Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin.
Topics: Acyl Coenzyme A; Adiponectin; AMP-Activated Protein Kinases; Animals; Fatty Liver; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypoglycemic Agents; Ion Channels; Liver; Liver Glycogen; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondrial Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Uncoupling Protein 2 | 2010 |
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Topics: Aging; Animals; Antioxidants; Dietary Fats; Fatty Liver; Gene Expression; Hepatitis; Liver; Male; Metabolic Syndrome; Mice; Mice, Knockout; Mitochondria, Liver; Oxidative Stress; PPAR gamma; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2010 |
The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats.
Topics: Adiponectin; Adipose Tissue; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.
Topics: Adenoviridae; Anilides; Animals; beta-Galactosidase; Choline; Diet; Fatty Liver; Genetic Vectors; Inflammation; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Methionine; Mice; Mice, Inbred C57BL; PPAR gamma; Random Allocation; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats.
Topics: Acetylcysteine; Animals; Anticonvulsants; Body Weight; Chemical and Drug Induced Liver Injury; Convulsants; Curcumin; Eating; Fatty Liver; Free Radical Scavengers; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Mice; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Rosiglitazone; Seizures; Thiazolidinediones; Valproic Acid | 2010 |
Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
Topics: Animals; Cells, Cultured; Drug Evaluation, Preclinical; Fatty Liver; Gene Expression Regulation, Enzymologic; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Mice; PPAR gamma; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Rosiglitazone; Sirtuins; Thiazolidinediones | 2011 |
Effect of silybin on high-fat-induced fatty liver in rats.
Topics: Animals; Antioxidants; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Fatty Liver; Homeostasis; Hypoglycemic Agents; Insulin Resistance; Lipid Peroxidation; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Rosiglitazone; Silybin; Silymarin; Thiazolidinediones | 2011 |
Rosiglitazone protects diabetic rats from liver destruction.
Topics: Animals; Apoptosis; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Fas Ligand Protein; Fatty Liver; In Situ Nick-End Labeling; Liver; Liver Diseases; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2011 |
Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Transporter Type 4; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligonucleotides, Antisense; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.
Topics: Adipokines; Adipose Tissue; Adiposity; Animals; Blood Glucose; Body Composition; Diet, High-Fat; Fatty Liver; Fluorobenzenes; Homeostasis; Insulin Resistance; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Pyrimidines; Resistin; Rosiglitazone; Rosuvastatin Calcium; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Thiazolidinediones; Triglycerides | 2012 |
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.
Topics: Adolescent; Adult; Age Factors; Australia; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; Cell Proliferation; Child; Child, Preschool; Europe; Fatty Liver; Gastric Bypass; Humans; Immunohistochemistry; Keratin-7; Liver; Liver Cirrhosis; Missouri; Non-alcoholic Fatty Liver Disease; Risk Factors; Rosiglitazone; Stem Cells; Thiazolidinediones; Treatment Outcome | 2013 |
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Muscle, Skeletal; Oxazines; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Fatty Liver; Hyperglycemia; Insulin Resistance; Leptin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Leptin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats.
Topics: Animals; Fatty Liver; Hepatomegaly; Hypoglycemic Agents; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.
Topics: 3T3 Cells; Animals; Breast; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cyclin D1; Ecdysterone; Epithelial Cells; Fatty Liver; Female; Gene Expression Regulation; Humans; Mice; Mice, Mutant Strains; Mice, Transgenic; Models, Molecular; Mutation; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Reference Values; Repressor Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 2003 |
Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Female; Hypoglycemic Agents; Liver; Male; Mice; Mice, Congenic; Pharmacogenetics; Phenotype; Phosphatidylcholines; Rosiglitazone; Thiazolidinediones | 2005 |
[Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development].
Topics: Animals; Blood Glucose; Cholesterol; Dietary Fats; Fatty Liver; Hypercholesterolemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Peptides; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Creatine kinase elevation in a patient taking rosiglitazone.
Topics: Adult; Creatine Kinase; Fatty Liver; Humans; Hypoglycemic Agents; Isoenzymes; Male; Rosiglitazone; Thiazolidinediones | 2005 |
Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.
Topics: Adiponectin; Analysis of Variance; Animals; Biomarkers; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin; Leptin; Male; Mice; Mice, Congenic; Mice, Inbred NOD; Mice, Obese; Obesity; Phenotype; Plasminogen Activator Inhibitor 1; Quantitative Trait, Heritable; Recombination, Genetic; Resistin; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2006 |
Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.
Topics: Animals; Cardiolipins; Cardiovascular System; Choline-Phosphate Cytidylyltransferase; Crosses, Genetic; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred NOD; Mice, Obese; Mitochondria, Heart; Phosphatidylcholines; Phosphatidylethanolamine N-Methyltransferase; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Dietary Fats; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; fas Receptor; Fatty Liver; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2006 |
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetimibe; Fats; Fatty Liver; Hypoglycemic Agents; Lipid Peroxidation; Liver; Male; Metformin; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rosiglitazone; Tetrazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Apoptosis; Body Weight; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Leptin; Linoleic Acids, Conjugated; Lipid Metabolism; Lipoproteins, VLDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides | 2007 |
The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Exercise Therapy; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Transaminases; Treatment Outcome; Vasodilator Agents | 2007 |
Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunoenzyme Techniques; Insulin; Interleukin-1beta; Interleukin-6; Lipid Peroxidation; Luminescent Measurements; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
[An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].
Topics: Animals; Cyclooxygenase 2; Fatty Liver; Hypoglycemic Agents; I-kappa B Kinase; Male; NF-kappa B; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2007 |
Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Fatty Liver; Lipid Peroxidation; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microscopy, Electron; Mitochondria, Liver; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tyrosine | 2007 |
The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis.
Topics: Adult; Biopsy; Dose-Response Relationship, Drug; Energy Metabolism; Fatty Liver; Female; Hepatocytes; Humans; Hypoglycemic Agents; Inclusion Bodies; Liver; Male; Mitochondria, Liver; Prospective Studies; Rosiglitazone; Thiazolidinediones | 2007 |
[Effects of rosiglitazone on Kruppul-like factor 6 (KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis].
Topics: Animals; Fatty Liver; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Liver; Male; PPAR gamma; Proto-Oncogene Proteins; Rats; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1 | 2007 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Rosiglitazone; Syndrome; Thiazolidinediones | 2007 |
Effects of rosiglitazone on methionine-choline deficient diet-induced nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Choline; Diet; Disease Models, Animal; Fatty Liver; Liver; Methionine; Mice; Mitochondria, Liver; Rosiglitazone; Thiazolidinediones | 2007 |
PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Topics: Animals; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression Profiling; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; PPAR alpha; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2008 |
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2001 |